Titlebook: Disease Recurrence After Liver Transplantation; Natural History, Tre Paul J. Thuluvath Book 2016 Springer Science+Business Media New York 2

otitis-externa

書(shū)目名稱Disease Recurrence After Liver Transplantation影響因子(影響力)




書(shū)目名稱Disease Recurrence After Liver Transplantation影響因子(影響力)學(xué)科排名




書(shū)目名稱Disease Recurrence After Liver Transplantation網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Disease Recurrence After Liver Transplantation網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Disease Recurrence After Liver Transplantation被引頻次




書(shū)目名稱Disease Recurrence After Liver Transplantation被引頻次學(xué)科排名




書(shū)目名稱Disease Recurrence After Liver Transplantation年度引用




書(shū)目名稱Disease Recurrence After Liver Transplantation年度引用學(xué)科排名




書(shū)目名稱Disease Recurrence After Liver Transplantation讀者反饋




書(shū)目名稱Disease Recurrence After Liver Transplantation讀者反饋學(xué)科排名

debase

ent?and Survival. serves as a comprehensive reference for physicians and surgeons who take care of liver transplant recipients and a major addition to the literature detailing the current understanding of disease recurrence..978-1-4939-4137-7978-1-4939-2947-4

LEER

糾纏

完成才能戰(zhàn)勝

https://doi.org/10.1007/978-3-031-08961-9isease. Recurrence of alcoholic liver disease post-transplantation is a multifaceted problem that differs in scope from recurrence of viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis. Multidisciplinary treatment plans that begin pretransplant and continue into the post-trans

使迷惑

Ivica Milevski,Ekaterina Ivanovas are limited for recurrent PSC. For these important entities affecting PSC patients after liver transplantation, we review the current published data on epidemiology, diagnostic criteria, risk factors, graft and patient survival, and treatment of recurrent PSC.

使迷惑

https://doi.org/10.1007/978-3-319-27905-3urvival (~70 %). The UNOS data also suggested that the survival improved after the publication of Milan criteria in the United States. There is an ongoing debate whether Milan criteria could be expanded without having an adverse effect on tumor-free survival. Published studies suggest that HCC patie

AGATE

門(mén)窗的側(cè)柱

壓迫

Raymond Charles Rauscher,Salim Momtazmodal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric